KHN702

KHN702 is a **highly selective NaV1.8 (Sodium channel protein type 10 alpha subunit) inhibitor**, developed as a **novel non-opioid analgesic**. It is a **small molecule** classified as a Class 1 innovative drug in China, designed to treat pain without the addictive potential associated with opioid medications. Developed by Chengdu Kanghong Pharmaceutical Group, KHN702 demonstrated strong therapeutic effects in preclinical pain models and has shown good safety and tolerability in early studies. KHN702 is being evaluated in phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, with administration as oral tablets[1][2][3][4][5][8].